Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2017 Aug 15;7:8267. doi: 10.1038/s41598-017-07434-y

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2017

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

HEV is more sensitive than HBV to pegIFNα treatment in human-liver chimeric mice. HEV RNA was measured by qRT-PCR in feces of human-liver chimeric mice infected with HEV gt3 or HEV gt1 before and during 4 weeks (a, n = 3), 2 weeks (b, n = 4; e, n = 3). and single (c, n = 4) pegIFNα treatment. Horizontal gray bars indicate pegIFNα treatment duration and dosage in µg/kg (a,b). Arrow indicates time point of the single 30 µg/kg pegIFNα injection (c). One day after last dosage mice were sacrificed and viral load was determined in liver and bile (d). Non-treated infected mice were added as control (d). X-axes indicates number of pegIFNα injections (d). HBV DNA was measured in serum of HBV gtA infected human-liver chimeric mice before and during pegIFNα treatment, and one day after last treatment mice were euthanized and intrahepatic HBV DNA was measured (f, n = 6). ^#indicates 3 µg/kg pegIFNα dosages. All mice were transplanted with the same hepatocyte donor (HD2, a–f). Y-axes indicate log HEV RNA IU/gram (a–c,d left panel, e), log HEV RNA IU/ml (d right panel), and log HBV DNA copies/ml (f). X-axes indicate days post infection (a–c,e–f).